Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PAMA-co-PLAMA glycopolymer
- Development stage
- Preclinical
- Modality
- Gene Therapies, Nanoparticles → Drug Delivery Systems
01
Overview
PAMA-co-PLAMA glycopolymer is an experimental cationic gene delivery nanosystem specifically designed for targeting hepatocellular carcinoma (HCC). It is a copolymer of 2-aminoethyl methacrylate hydrochloride (PAMA) and 2-lactobionamidoethyl methacrylate (PLAMA), synthesized using activators regenerated by electron transfer (ARGET) atom transfer radical polymerization (ATRP). The PLAMA component features lactobionic acid moieties that serve as ligands for the asialoglycoprotein receptor (ASGPR), which is highly expressed on HCC cells, enabling receptor-mediated endocytosis. This glycopolymer forms 'glycoplexes' with therapeutic DNA, such as the HSV-TK suicide gene, providing a biocompatible and efficient platform for targeted gene therapy. In preclinical studies, it has demonstrated high transfection efficiency and potent antitumor activity, particularly when combined with low doses of docetaxel.
- Other names
- poly(2-aminoethyl methacrylate hydrochloride-co-poly(2-lactobionamidoethyl methacrylate)cationic glycopolymer gene delivery nanosystem
02
Targets
ASGPR (Asialoglycoprotein Receptor 1)
Beyond the preview
Go deeper on PAMA-co-PLAMA glycopolymer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PAMA-co-PLAMA glycopolymer.